GlassScriptPhysician profile
Narendra Kanamathareddy
NPI 1316355407
$777.12
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $245 · 2021: $85.57 · 2022: $186 · 2023: $65.43 · 2024: $29.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $363.97 | 2019-2023 | Xarelto |
| Pfizer INC. | $126.54 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $92.63 | 2019-2023 | Recarbrio, Dificid, Zerbaxa |
| Novartis Pharmaceuticals Corporation | $67.14 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $30.01 | 2020 | |
| Baxter Healthcare | $29.60 | 2024 | Hillrom - Life 2000 Ventilation System |
| Paratek Pharmaceuticals, INC. | $16.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.53 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.18 | 2019 | |
| Shire North American Group INC | $12.81 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendra Kanamathareddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.